Australia markets closed

Zhejiang Shouxiangu Pharmaceutical Co., Ltd. (603896.SS)

Shanghai - Shanghai Delayed price. Currency in CNY
Add to watchlist
18.99-0.61 (-3.11%)
At close: 03:00PM CST
Currency in CNY

Valuation measures4

Market cap (intra-day) 3.76B
Enterprise value 3.03B
Trailing P/E 14.07
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)4.88
Price/book (mrq)1.71
Enterprise value/revenue 3.96
Enterprise value/EBITDA 8.61

Trading information

Stock price history

Beta (5Y monthly) 0.32
52-week change 3-55.79%
S&P500 52-week change 326.76%
52-week high 344.00
52-week low 318.94
50-day moving average 321.81
200-day moving average 326.59

Share statistics

Avg vol (3-month) 31.82M
Avg vol (10-day) 31.43M
Shares outstanding 5198.24M
Implied shares outstanding 6198.24M
Float 8112.91M
% held by insiders 144.02%
% held by institutions 19.54%
Shares short 4N/A
Short ratio 4N/A
Short % of float 4N/A
Short % of shares outstanding 4N/A
Shares short (prior month ) 4N/A

Dividends & splits

Forward annual dividend rate 40.39
Forward annual dividend yield 42.05%
Trailing annual dividend rate 30.39
Trailing annual dividend yield 31.99%
5-year average dividend yield 41.00
Payout ratio 428.89%
Dividend date 3N/A
Ex-dividend date 420 June 2024
Last split factor 21.3:1
Last split date 326 May 2022

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)30 June 2024

Profitability

Profit margin 34.64%
Operating margin (ttm)10.27%

Management effectiveness

Return on assets (ttm)4.00%
Return on equity (ttm)12.57%

Income statement

Revenue (ttm)765.44M
Revenue per share (ttm)3.89
Quarterly revenue growth (yoy)-20.40%
Gross profit (ttm)N/A
EBITDA 258.13M
Net income avi to common (ttm)265.12M
Diluted EPS (ttm)1.35
Quarterly earnings growth (yoy)-14.10%

Balance sheet

Total cash (mrq)1.37B
Total cash per share (mrq)6.89
Total debt (mrq)634.91M
Total debt/equity (mrq)28.76%
Current ratio (mrq)3.70
Book value per share (mrq)11.14

Cash flow statement

Operating cash flow (ttm)282.51M
Levered free cash flow (ttm)-497.99M